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life.[1] Although bone tissue possesses the 
self-repair ability, the large critical-size 
bone defect cannot regenerate without 
bone grafting and 5–10% fractures show 
nonunion or delayed healing.[2] As the 
noncoding RNAs (≈22 nt), microRNAs 
(miRNAs) can regulate the fundamental 
physiological process in various organ-
isms through degrading and repressing 
the expressions of target RNAs.[3] In recent 
years, various miRNAs have shown the 
capacity to positively regulate the osteo-
genic genes expressions and osteogenesis 
in vitro and in vivo through multiple sign-
aling pathways.[4] Unfortunately, naked 
miRNAs are difficult to enter cells and 
also easy to be degraded by the nuclease 
under physiological environment. Dif-
ferent gene vectors have been synthesized 
and used to deliver miRNA for enhanced 
bone tissue formation.[5]
Viral vectors exhibited good miRNA 
transfection efficiency but also showed 
some negative effects such as infection 
and immunogenicity.[6] To avoid the prob-
lems of viral vectors, nonviral vectors 
including cationic polymers and liposomes were widely inves-
tigated for miRNA delivery in vitro and in vivo.[7–9] However, 
the miRNA delivery of cationic polymers and liposomes was 
always unsatisfactory due to the cytotoxicity, low transfection 
efficiency, and serum stability.[10] It is necessary to develop next 
generation nonviral vectors with good osteogenic biocompat-
ibility, high miRNA loading and protecting ability, and excellent 
miRNA delivery efficiency.
As compared to conventional inorganic biomaterials, bio-
active glasses (BGs) have inspired intensive research interest in 
bone tissue regeneration due to their remarkable osteoblast bio-
compatibility, bioactivity including the chemical bone-bonding 
ability and gene activation properties.[11–16] Therefore, BG nano-
particles (BGNs) have a great potential to be employed as novel 
bioactive nonviral gene vectors for tissue regeneration and 
gene therapy. Up to now, few studies reported the gene delivery 
applications based on BGNs. For instance, Kim used amine-
functionalized mesoporous BGNs to deliver small interfere 
RNA (siRNA) and 5.18% loading efficiency was obtained.[17] 
Chen and co-workers developed an amine-modified radial 
mesoporous BGNs which showed good DNA delivery efficiency 
and protection ability.[18] Although some positive results of 
Bioactive glass nanoparticles (BGNs) have attracted much attention in drug 
delivery and bone tissue regeneration, due to the advantages including biodeg-
radation, high bone-bonding bioactivity, and facile large-scale fabrication. How-
ever, the wide biomedical applications of BGNs such as efficient gene delivery 
are limited due to their poor pore structure and easy aggregation. Herein, for 
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significantly improves the osteogenic differentiation of bone marrow stromal 
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be a highly efficient nonviral vector for various gene therapy applications. The 
study may provide a novel strategy to develop highly gene-activated bioactive 
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Bone Regeneration
1. Introduction
The traumas and diseases resulted bone tissue loss has become 
huge social problems seriously affecting the human quality of 
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BGNs in DNA and siRNA delivery were achieved, the amine-
functionalization was necessary to make BGNs positively 
charged for loading genes. The limited surface positive charge 
density usually resulted in the low loading and poor trans-
fection efficiency. Additionally, the charged surface of nano-
particles may also cause the nonspecific protein adsorption and 
cytotoxicity in vivo applications.[19]
Recently, our group demonstrated that BGNs could bind 
miRNA directly without any surface cationic modification and 
release them in cellular environment, suggesting the great 
potential of BGNs as the next generation nonviral vectors for 
enhanced gene therapy.[20] Through the strong interaction 
between calcium in BGNs and phosphates in miRNA, BGNs 
showed a significantly high miRNA loading and intracellular 
transfection efficiency, as compared to conventional silica 
nanoparticles.[20] Even so, as an ideal gene vector, the small 
mesopore size (<5 nm) and pore volume (<0.04 m3 g−1) of 
BGNs was still not satisfied in biomedical applications.[21,22] It 
is very worthwhile to develop BGNs with the novel nanostruc-
ture for enhanced gene delivery applications.
Branched polyethyleneimine (PEI) is a common functional 
macromolecule that usually used for gene delivery, but is rarely 
employed as template to direct the formation of nanostruc-
ture.[23] Based on the fact that the abundant amino in PEI can 
catalyze the hydrolysis of silica precursor and the branched 
structure may direct the formation of large pores, here, for the 
first time, we developed monodispersed bioactive glass nano-
clusters (BGNCs) with ultralarge pores and controlled size. 
We also demonstrated their highly efficient miRNA delivery, 
activated osteogenic genes expression in vitro and enhanced 
critical-sized bone defect regeneration in vivo, as compared to 
conventional BGNs.
2. Results and Discussion
2.1. Preparation and Characterization of Monodispersed BGNCs
In this work, we have developed a facile and simple method to 
fabricate the monodispersed BGNCs by employing a branched 
macromolecules PEI as structure director and reaction cata-
lyst. The synthesize process, reaction mechanism, and poten-
tial miRNA delivery application is illustrated in Figure 1. On 
one hand, the amine-based polymer PEI could serve as an in 
situ catalyst for silica precursor hydrolysis and condensation. 
On the other hand, PEI could self-assemble into the frame-
work during condensation reactions, therefore act as a pore 
expansion agent to generate ultralarge pores (Figure 1A). 
Based on the strong gene binding ability and ultralarge 
pores, BGNCs could serve as a high efficient nonviral vector 
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Figure 1. Schematic illustration showing the fabrication and miRNA delivery application of BGNCs. A) Synthesis of BGNCs by a branched PEI-assistant 
sol–gel process. B) Ultrahigh miRNA loading ability and binding mechanism. C) BGNC-based miRNA delivery to regulate osteogenic activity of stem 
cells in vitro and bone regeneration in vivo.
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to deliver miRNA for accelerating bone tissue regeneration 
(Figure 1B,C).
The final nanostructure and size of the synthesized BGNCs 
could be tuned by the concentration of PEI during the reac-
tion. As shown in Figure 2A–D, BGNCs showed a typical 
nanoclusters morphology and large mesopores. Specifically, 
the morphology and size of BGNCs could be effectively tai-
lored by the mass ratio of PEI. 10%BGNCs, 20%BGNCs, and 
30%BGNCs exhibited a size around 100, 200, and 450 nm, 
respectively (Figure S1, Supporting Information). Generally, 
the monodispersed size of BGNCs was increased from 100 to 
450 nm with the increase of PEI contents. However, when the 
mass ratio of PEI decreased to 6%, BGNCs presented a nonu-
niform size with a wide range from 50 to 500 nm (Figure S2, 
Supporting Information). Under the high concentration of PEI, 
the rapid hydrolysis and condensation of silanol groups took 
place, leading to the fast formation of silica network. Then the 
smaller nanoclusters would aggregate and produce a larger one 
after further reaction. However, at the low concentration of PEI, 
the incomplete hydrolysis and condensation of silanol groups 
would result in the nonuniform size and irregular morpholo-
gies of BGNCs. Through varying the amount of PEI, the size, 
microstructure and morphology of BGNCs could be controlled 
facilely. In particular, through increasing the amount of precur-
sors and solvents, the large-scale production of BGNCs can be 
achieved, and their morphology/size distribution were almost 
unchanged (Figure S3, Supporting Information).
BGNCs exhibit a strong and broad band at 2900–3500 cm−1 
and 1600 cm−1 which were attributed to the stretching and 
bending vibration of hydroxyls (Figure 2E). The characteristic 
peaks of BGNCs can be found at 1060, 800, and 480 cm−1.[24] 
The strong absorbance at 1060 cm−1 is assigned to the stretch 
vibration of Si-O-Si, while the peaks at 800 and 480 cm−1 were 
owing to the bending vibration of Si-O-Si. The broad peak in 
XRD patterns indicated the typical amorphous structure of 
BGNCs (Figure 2F). The energy dispersive spectroscopy (EDS) 
analysis confirmed the chemical composition of BGNC con-
taining Si and Ca (Figure 2G). To investigate the pore structure 
and property of BGNCs, the specific surface area, pore volume, 
and pore size distribution of BGNCs and BGNs were deter-
mined (Figure 2H; and Figure S4, Supporting Information). 
The Brunauer–Emmet–Teller (BET) surface area of 10%BGNCs 
and BGNs are calculated to be 213.611 and 236.620 m2 g−1, 
respectively (Table S2, Supporting Information). The 10%BGNC 
showed a total pore volume of 1.138 cm3 g−1 and average pore 
size of 20.056 nm, which were almost 30 and 6 times higher 
than those of BGNs (0.0342 cm3 g−1 and 3.468 nm) (Table S2, 
Supporting Information). The ultralarge porous structure may 
endow BGNCs the high gene storage and delivery ability for 
efficient bone tissue regeneration.
2.2. Apatite-Forming Evaluation of BGNCs
BGs have been successfully exploited as a kind of highly bio-
active material for bone regeneration because of its improved 
apatite-forming ability as compared to other conventional 
bioactive ceramics. The well-formed apatite layer on BGs in 
physiological environment can bond to bone and even stimu-
late new bone growth.[25,26] In this work, the apatite-forming 
ability of the synthesized BGNCs was studied in detail. After 
soaking in simulated body fluids (SBF) for 3 d, the flake-like 
nanocrystals were observed clearly on BGNCs (Figure 3A). Fur-
ther Fourier transform infrared (FTIR) spectra indicated the 
presence of three new peaks at 550, 605, and 950 cm−1 which 
are associated to the vibration of crystalline P-O in crystalline 
PO43− (Figure 3B).[27] The characteristic peaks of hydroxyapatite 
nanocrystals (JCPDS 09-432) could also be observed from the 
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Figure 2. Structure and characterizations of BGNCs. TEM images showing the monodispersed cluster-like morphology and nanoscale size of A) 6% 
BGNC, B) 10% BGNC, C) 20% BGNC, D) 30% BGNC. E) FTIR spectra exhibiting chemical structure of BGNCs. F) XRD patterns presenting the typical 
amorphous structure of BGNCs. G) EDS analysis identifying the element composition of BGNCs. H) Pore size distributions of BGNs and BGNCs 
based on N2 adsorption–desorption analysis.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1700630 (4 of 11)
www.advancedsciencenews.com www.advhealthmat.de
XRD pattern at 26° (002), 32° (211), and 46° (222), which further 
implied the formation of hydroxyapatite layer (Figure 3C).[27] By 
investigating the bioactivity of BGNC utilizing FTIR, XRD, and 
TEM, we can reasonably conclude that the obtained BGNCs 
possess excellent apatite-forming ability, and the superior bio-
activity make it can be widely used in bone tissue repair and 
regeneration.
2.3. Ultrahigh miRNA Loading and Stability of BGNCs
Compared with BGNs and conventional mesoporous mate-
rials, BGNCs possess ultralarge mesopores and may have high 
miRNA loading ability. Figure 4A–C reveals the miRNA loading 
ability of BGNCs at different weight ratios (0–64 mg µg−1). The 
miRNA was retarded completely by BGNCs at a weight ratio of 
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Figure 3. Apatite-forming ability evaluation of BGNCs after soaking in SBF for 3 d. A) TEM image showing the apatite nanocrystals formed on surface 
of BGNCs. B) FTIR spectra indicating the chemical structure of new formed hydroxyapatite nanocrystals on BGNCs. C) XRD patterns exhibiting the 
characteristic peaks of hydroxyapatite nanocrystals on BGNCs (JCPDS No 09-432).
Figure 4. Ultrahigh miRNA loading and protection capacity of BGNCs. Gel retardation pictures showing the miRNA binding ability of A) BGNCs and 
B) BGNs with different weight ratios to miRNA (2–64 mg µg−1). C) Quantitative miRNA loading efficiency of BGNC and BGN at 40 and 80 µg mL−1 
(**p < 0.01, n = 5). D) Antinuclease degradation ability of various miRNA complexes after soaking in serum solution for 24 h. E) Quantitative miRNA 
intact percentage of different samples.
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4:1 (Figure 4A), overpassing that of BGNs (8:1) (Figure 4B). The 
quantitative analysis showed that BGNCs demonstrated sig-
nificantly high miRNA loading efficiency (3.8 µg mg−1) which 
was almost 19 times high compared to BGNs (0.2 µg mg−1) 
at the same nanoparticles concentration (40 µg mL−1). The high 
loading ability of BGNCs was probably due to two reasons. On 
one hand, the Ca2+ in BGs framework has a strong binding 
affinity to the phosphates groups in miRNA structure, which 
contributed to their loading ability.[28] This strong gene binding 
mechanism of BGs through a metal ion complex process has 
been demonstrated by our previous report.[20] In addition to 
the calcium-miRNA complex interaction, the ultralarge porous 
structure of BGNCs should also contribute to their high miRNA 
loading amount. BGNCs have a 30 times and 6 times high 
pore volume and mean pore size comparing with BGNs, thus 
showed the ultrahigh miRNA loading efficiency. The large pore 
volume and size derived high gene or drug loading performance 
was reported everywhere, especially for mesoporous inorganic 
nanomaterials.[29,30] The antinuclease degradation ability of 
miRNA complexes (BGNC@miRNA, BGN@miRNA) was 
investigated by incubating them with serum, Lipo, and naked 
miRNA were chose as controls (Figure 4D,E). It can be found 
that both BGNCs and BGNs could protect the miRNA from 
the enzymolysis by nuclease within 24 h, and almost no sig-
nificant degradation of miRNA could be detected (Figure 4D). 
Naked miRNA was degraded completely after 3 h (Figure 4E). 
However, after 24 h incubation, more than 80% of the intact 
miRNA could be detected in BGNC@miRNA group, but only 
50% and 35% of intact miRNA could be detected in BGN@
miRNA and Lipo@miRNA group, suggesting the excellent 
miRNA protection ability of BGNCs (Figure 4E). The excellent 
miRNA protecting ability of BGNC was mainly owing to 
the large pore size and volume of BGNCs. On one hand, the 
large pores created more chances for the interaction between 
Ca2+ and the guest genes, therefore significantly enhanced 
the binding forces to miRNA and avoided the fast release of 
miRNA. On the other hand, the large pore volume of BGNCs 
could effectively protect miRNA from enzymolysis. The ultra-
high miRNA loading and excellent antinuclease degradation 
ability of BGNCs enabled their promising application in gene 
delivery.
2.4. In Vitro Cell Biocompatibility, miRNA Transfection, 
and Osteogenic Differentiation
The bone marrow stromal stem cells (BMSCs) viability and pro-
liferation behavior was investigated through incubating with 
BGNCs at different concentrations (40–160 µg mL−1). After 
culture with BGNCs for 1–5 d, cells viability showed a great 
increase and no significant difference was observed compared 
with tissue culture plate (TCP) control, indicating their high 
biocompatibility (Figure 5A). Further Live–Dead staining fluo-
rescent images exhibited that cells showed good attachment 
morphology after incubated with BGNCs at different concentra-
tions and no dead cells were observed after 1 d (Figure 5B–D). 
These results were consistent with previous findings that BG-
based bioactive materials have a good cell biocompatibility 
especially the osteoblasts.[31]
BMSCs were used as model cells to investigate the miRNA 
transfection efficiency of BGNCs. After transfected for 48 h, 
the significant green fluorescence of miRNA in the cells was 
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Figure 5. Cellular biocompatibility evaluation. A) BMSCs viability and proliferation of cells after treated with BGNCs at concentrations of 40, 80, and 
160 mg mL−1 (*p < 0.05 and **p < 0.01, n = 5). B–D) Live–Dead staining fluorescence images of cells after culture with BGNCs for 1 d at B) 40 mg mL−1, 
C) 80 mg mL−1, and D) 160 mg mL−1 (scale bar: 200 µm).
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observed clearly in BGNCs group compared with Lipo/BGN 
group, suggesting the high efficient miRNA intracellular 
delivery of BGNCs (Figure 6A). The magnified confocal scan-
ning microscope (CLSM) images of cells showed that miRNA 
was mainly distributed around the cell nucleus, implying that 
miRNA was successfully transported into the cells. Moreover, 
quantitative analysis based on CLSM images showed that the 
mean fluorescent intensity of BGNCs group was significantly 
higher than that of Lipo and BGNs group (Figure 6B). The flow 
cytometry examination further demonstrated the difference of 
miRNA transfection efficiency for various groups (Figure 6C). 
Almost negligent transfection ability (2.3%) in BMSCs was 
found in naked FAM-labeled miRNA group (NC). BGNCs 
group demonstrated significantly high miRNA transfection effi-
ciency (45.3%), as compared to BGNs group (40.1%) and com-
mercial Lipo group (35.1%). The excellent miRNA delivery and 
transfection efficiency of BGNCs should be attributed to their 
ultralarge pore structure and ultrahigh miRNA loading effi-
ciency, as well as strong miRNA protection capacity.
In this study, the used miRNA-5106 (miR-5106) has been 
shown to have positive osteogenic inductive ability through 
upregulating several osteogenic genes expressions.[32] Here, 
we investigate the effect of BGNC-based miR-5106 delivery on 
osteogenic differentiation markers expressions (Runx2, Opn, 
and Alp) in BMSCs by qRT-PCR analysis (Figure 7). As com-
pared to pure BGNs and BGNCs group, BGN@miRNA and 
BGNC@miRNA group showed the significantly high Runx2, 
Opn, and Alp expression level during the culture periods of 7 
and 14 d, which suggested that BGNs and BGNCs could effi-
ciently deliver miR-5106 to enhance osteogenic differentiation 
of cells. Additionally, Runx2, Opn, and Alp expression increased 
gradually in all groups during 14 d. At day 14, the Runx2, Opn, 
and Alp expression in BGNC@miRNA group was 1.5 times, 
2.0 times, and 1.8 times higher than those in BGN@miRNA 
group. These results further indicated that BGNCs could effi-
ciently deliver miRNA and enhance the osteogenic differentia-
tion of BMSCs, and may have a great potential for in vivo bone 
regeneration as a new gene-activated bioactive materials.
2.5. In Vivo Bone Tissue Regeneration
The promising in vitro results of BGNCs, including miRNA 
transfection and osteogenic differentiation, encouraged us 
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Figure 6. MiRNA transfection efficiency evaluation of BGNCs. A) CLSM images of BMSCs after transfected with BGNC@miRNA for 48 h, using BGN 
and Lipo as controls (scale bar: 100 µm). The miRNA was labeled as green by FAM and cell nuclear was stained as blue by Hoechst. B) Quantitative 
fluorescent intensity analysis of cells based on CLSM images after transfected by various miRNA complexes. C) Flow cytometry analysis of cells after 
transfected by various miRNA complexes, demonstrating the miRNA transfection efficiency (*p < 0.05, **p < 0.01, n = 5).
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to investigate the effect of BGNCs on in vivo bone repair and 
regeneration. The bone regeneration ability of BGNCs and 
BGNC@miRNA was investigated by a rat critical sized cranial 
defect model. After implantation in defect site for four weeks, 
the bone tissue samples were removed and were scanned by 
an X-ray microCT systems to evaluate the newly formed bone 
tissue. As shown in Figure 8A, blank NC group shows little new 
bone formation near the defects border, but newly formed bone 
tissue could be clearly observed in BGNCs and BGNs group. In 
addition, large amount of new bone formation could be found 
after treated by BGNC@miRNA group, which was significantly 
higher than BGNC/BGN/BGN@miRNA group. Further quan-
titative bone tissue analysis exhibited that BGNC@miRNA 
group demonstrated a significantly high new bone volume and 
trabecular thickness, compared with BGNCs, BGN@miRNA, 
and BGNs group (Figure 8B,C).
The newly formed bone tissues were further exam-
ined through hematoxylin and eosin (H&E) and Masson’s 
trichrome staining (Figure 9). H&E staining showed the 
results of inflammation response and new bone formation (NB 
in red). All groups exhibited the low inflammation response 
in defect site. There was minimal new bone formation in NC 
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Figure 7. Osteogenic gene maker expressions of cells after induced for 7 and 14 d by various miRNA-5106 complexes. A) Runx2; B) Opn; C) Alp. Sig-
nificantly enhanced Runx2, Opn, Alp expressions were observed at day 14 in BGNCs group, as compare to other groups. The tissue culture plate (TCP) 
with naked miRNA-5106 was used as negative control (NC) (*p < 0.05, **p < 0.01, n = 3).
Figure 8. In vivo bone tissue regeneration of BGNs, BGNCs, BGN@miRNA, BGNC@miRNA after implantation in critical-sized defect for four 
weeks. A) MicroCT images showing the repair and reconstruction of frontage (up) and cross-section (down) in cranial defects (Scale bars = 5 mm). 
B,C) Quantitative analysis of new bone volume fraction B) and trabecular thickness C) calculated from the micro-CT images (*p < 0.05, **p < 0.01, n = 3). 
Significantly high new bone formation was observed in BGNC@miRNA group.
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group and significantly increased bone tissue was observed in 
BGN-based groups. BGNC@miRNA group induced the best 
bone formation after four weeks implantation in defect site. 
Masson trichrome staining was used to identify the collagen 
deposition in bone defect site after repair. Significantly high 
and dense collagen deposition (dark site) could be found in 
BGNCs and BGNC@miRNA group. Limited positive staining 
in NC group suggested their low bone collagen deposition. The 
histological results were in accordance with those of microCT, 
demonstrating the rapid bone regeneration ability of BGNC@
miRNA.
In bone tissue regeneration, conventional bioactive 
materials including bioactive glass and calcium phosphate 
ceramics-based nanocomposites have shown promising 
results in enhancing bone tissue formation.[33,34] The gene-
activated bioactive materials with intrinsic gene loading 
capacity are less demonstrated, although they are rather 
important for tissue regeneration and disease therapy. In 
this paper, the developed BGNCs exhibited ultrahigh miRNA 
loading and excellent delivery performance for enhanced 
osteogenic differentiation and bone formation. Inorganic 
nanoparticles with ultralarge pores have shown special advan-
tages in drug and gene delivery applications.[35] As novel 
nonviral gene vectors, compared with silica nanoparticles, 
BGNs present inherent gene binding ability through their 
unique metal-organic complex mechanism.[20] Unfortunately, 
the gene may be only loaded on the surface in BGNs due to 
their small pore structure (below 5 nm). Herein, by using 
branched PEI as a template, BGNCs with a monodispersed 
size, and ultralarge porous structure were successfully fabri-
cated. Then, the ultrahigh miRNA loading efficiency, signifi-
cantly enhanced osteogenic genes expressions, and bone for-
mation were achieved through BGNCs-mediated delivery. As 
compared to conventional nonviral vectors such as liposomes 
and cationic polymers, BGNCs possess several advantages. 
First, large-scale fabrication of BGNCs could be achieved fac-
ilely, which is very important for wide clinical applications. 
Second, BGNCs show high biocompatibility and intrinsic 
osteogenic activity, which may have synergetic effect with 
miRNA delivery in bone formation. Based on these excellent 
properties, BGNCs may have great potential as next-genera-
tion nonviral vector to deliver genes for tissue regeneration 
and disease therapy.
3. Conclusion
In summary, we developed a novel and simple strategy 
for large-scale synthesis of monodispersed BGNCs with 
ultralarge mesopores (≈20 nm) and tailored nanosize (100–
500 nm) using branched PEI as the template and catalyst. 
BGNCs show an excellent apatite-forming ability due to their 
high surface area and pore structure. BGNCs can support 
and enhance BMSC attachment and proliferation, indicating 
their good cellular compatibility. Significantly, BGNCs demon-
strate ultrahigh miRNA loading efficiency which is 19 times 
higher than conventional BGNs. BGNCs can protect, deliver 
miR-5106 to enhance the osteogenic differentiation of BMSCs 
and significantly promote the new bone formation in critical 
sized cranial defects in rats. Therefore, based on the excel-
lent pore structure, unique gene binding ability and biosafty, 
BGNCs would be a favorable vehicle to deliver various genes 
Figure 9. Histological analysis of new bone formation after 4 w implantation in defect site. H&E staining demonstrates the new bone formation (NB) 
dependent on various samples; Masson staining exhibits the collagen deposition (dark blue) in newly formed bone tissue. BGN@miRNA, BGNC, and 
BGNC@miRNA group significantly enhanced bone formation and collagen deposition in vivo.
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for enhancing tissue regeneration and cancer therapy. As a 
new-generation gene vector, further in vivo tissue regenera-
tion and cancer therapy applications based on BGNCs should 
be demonstrated.
4. Experimental Section
Materials: PEI (Mn 25000), tetraethyl orthosilicate (TEOS), 
triethylphosphate (TEP), calcium nitrate tetrahydrate (CN), ethyl 
alcohol (99% ETOH), tris, agarose, boric acid were purchased from 
Sigma-Aldrich. Opti-MEM, AlamarBlue cell viability kit, LIVE–DEAD 
mammalian cell viability stain kit, Hoechst 33342 and 4-(2-hydroxyethyl)-
1-piperazine-N′-2-ethanesulfonic acid (HEPES) were obtained from 
Thermo Fisher. Normal miRNA and carboxyfluorescein (FAM) labeled 
miRNA (miR-5106) were bought from Genepharma (China). Deionized 
water (DW) was used for all experiments. All chemicals were used as 
received without further purification.
Synthesis and Characterizations of Monodispersed BGNCs: 
Monodispersed BGNCs with ultralarge pores were fabricated via a 
sol–gel method using PEI as the catalyst and structure-directing agent. 
Briefly, PEI was dissolved in 500 mL of ethyl alcohol/water solution 
(3/1 = v/v) under magnetically stirring, followed by addition of 10 mL 
TEOS, and the resulting mixture was stirred for 30 min. Then TEP and 
CN were added to the reaction system in sequence and the reaction 
was kept at 40 °C for 3 h. The resulted product was collected by 
centrifugation and purification by washing with ETOH/DW for several 
times. The nanoparticle size of BGNCs was controlled through adding 
different amount of PEI. Specifically, the mass ratio of TEOS to PEI were 
1:0.06, 1:0.1, 1:0.2, and 1:0.3, and the final products were denoted as 
6% BGNCs, 10% BGNCs, 20% BGNCs, and 30% BGNCs. Additionally, 
conventional BGNs with the same chemical composition as BGNCs 
were prepared according to the previous report and used as a control 
material in this study.[36]
The nanostructure and morphology of BGNCs were observed 
by a TEM (HT-7700, Hitachi). The phase, chemical structure and 
composition of BGNCs were investigated by XRD (DMAX/A, Rigaku), 
FTIR spectroscopy (Nicolet 6700, Thermo Sci.) and X-ray EDS (Quanta 
250 FEG, FEI). Nitrogen adsorption–desorption measurement and BET 
method was carried out to analyze the specific surface area and pore 
size distributions of BGNCs (Quadrasorb SI-3, Quantachrome). UV–
vis absorption spectra were recorded on a UV–vis spectrophotometer 
(Lambda 35, PerkinElmer) at room temperature.
Apatite-Forming Bioactivity Evaluation of BGNCs: The apatite-forming 
investigation of BGNCs was performed in simulated body fluids (SBF) 
for 3 d, according to the previous report.[36] In a typical process, BGNCs 
was soaked into SBF at a concentration of 10 mg mL−1 and shaken 
at 100 rpm at 37 °C for predetermined times. The morphology and 
structures of apatite formed on the surface of BGNC was observed by 
TEM, and further analyzed by FTIR and XRD.
Formation and Stability Analysis of BGNC@miRNA Complexes: Based 
on the optimum monodispersed size and controlled morphology, 
10% BGNCs were used in further miRNA loading, delivery, and 
biocompatibility studies. The miRNA (miR-5106 from GenePharma, 
Shanghai) loading capacity and stability of BGNCs was analyzed using 
a gel retardation assay,[37] BGNs were used as a control. Briefly, the 
BGNC@miRNA or BGN@miRNA complexes at different mass ratios 
ranging from 0:1 to 64:1 were prepared as the following procedure. 
Different amount of BGNCs/BGNs were mixed with 13 µg mL−1 
miRNA in HEPES and incubated for 30 min at 37 °C. Then the resulting 
complexes were loaded on 2% agarose gel to conduct the gel retardation 
assay (110 V for 15 min) on an electrophoresis system (HE120, 
Tanon). The mean intensity of miRNA bands and pictures-taking were 
investigated by a gel imaging system (Gel Doc XR+, Bio-rad). The 
binding percentage was calculated as the following equation 
D D D DBp a b / c b 100%( ) ( )= − − ×  (1)
where Bp is the miRNA binding percentage, Da is the densities of 
miRNA bands in the wells with BGNC/BGN, Dc represents the densities 
of miRNA bands in the wells without BGNC/BGN, and Db is the density 
of background, respectively.
The stability investigation of BGNC@miRNA complexes was 
performed in the presence of serum, using BGNs and commercial 
Lipofectamine 3000 (Lipo) as the controls. Briefly, BGNC@miRNA 
complexes solutions were added with 25% fetal bovine serum (FBS) and 
incubated for predetermined times (0–24 h). Afterward, ribonuclease 
inhibitor (RRI, Tiangen) was added to the solutions to inhibit the 
further degradation of miRNA. Then the samples were collected and 
treated with heparin and subsequently loaded on 2% agarose gel for gel 
retardation assay, the mean intensity of miRNA bands were analyzed by 
the gel imaging system.
Cytotoxicity Investigation: The cellular biocompatibility of BGNCs was 
carried out by using the BMSCs (from Cell Bank, Chinese Academy 
of Sciences, China), according to previous report.[32] The live cellular 
morphology and proliferation was evaluated by using a Live–Dead kit (Life 
Science) and alamar blue assay kit (Life Science), respectively. Briefly, 
cells were seeded in a 96 well plate at a density of 4000 cells per well 
and incubated in a growth medium (DMEM, 10% FBS, Life Sciences) in 
a humidified incubator at 37 °C with 5% CO2. After attachment for 24 h, 
the medium was removed, followed by adding the growth medium 
containing various BGNCs concentrations (40–160 µg mL−1). The cells 
were cultured with BGNCs for 1, 3, 5 d. At the predetermined time 
point, the cells were washed by phosphate buffered saline (PBS) for 
three times and incubated in 100 µL of Live–Dead solution for 45 min at 
37 °C. The live cell morphology was observed via an inverted fluorescent 
microscope (Olympus, IX53). After 1, 3, and 5 d incubation, the live cell 
viability was measured by using an Alamar Blue kit in accordance with 
the manufacture’s instruction. The live cell fluorescence was measured 
at an excitation/emission wavelength of 530/600 nm on a microreader 
(SpectraMax, Molecular Services). TCP without materials was used as a 
control. At least five species per sample was tested.
Transfection Efficiency Investigations: For demonstrating the delivery 
efficiency of miRNA by BGNCs, the cellular uptake and intracellular 
fluorescence expression of BGNC@miRNA complexes were evaluated 
by laser CLSM (FV1200, Olympus) and a flow cytometer (CytoFLEX, 
Coulter Beckman), using BGNs and Lipo as controls. For CLSM 
observation, cells were seeded on glass slides at a density of 5000 cells 
per well in a growth medium. After 24 h, cells were rinsed by PBS and 
incubated with the fluorescent labeled miRNA complexes (BGNC@
miRNA, BGN@miRNA, or Lipo@miRNA) in a transfection medium. 
After culture for 24 h, the medium was removed and cells were washed 
by PBS for three times. The cell nucleus was stained as blue by Hoechst 
(Life Technologies). Then the transfected cell images were observed 
under the CLSM.
Flow cytometer (CytoFLEX, Coulter Beckman) was used to evaluate 
the cellular uptake of miRNA-loaded 10%BGNC/BGN/Lipo. Typically, 
BMSCs transfected with miRNA-loaded 10%BGNC/BGN/Lipo were 
washed by Dulbecco’s phosphate buffered saline (Thermo Fisher 
Scientific) for two times, after trypsinization and centrifugation process, 
the cells were finally suspended in 100 µL PBS supplemented with 2% 
FBS and 100 µL of 4% paraformalclehyde. After incubated for 2 h at 
4 °C, the percentage of cells successfully transfected were analyzed by 
detecting the fluorescence intensity of samples through flow cytometry 
and analyzed by CytExpert software (Beckman Coulter).
Osteogenic Genes Expressions Examination: The BMSCs were 
transfected with different miRNA complexes and cultured for different 
times (7 and 14 d) for evaluating osteogenic genes expressions (Alp, 
Runx2, and Opn) using a quantitative real-time polymerase chain 
reaction (qRT-PCR, Bio-rad). The α-MEM (Sigma) supplemented 
with 10% FBS (Gibco), 50 mg mL−1 ascorbic acid, 10 × 10−3 m 
α-glycerophosphate (Sigma) and 10 × 10−9 m dexamethasone (Sigma) 
was used as osteogenic inductive medium. 10% BGNCs were used 
to load miRNA for osteogenic differentiation experiment. Typically, 
cells were seeded in a 24 well plate at a density of 2 × 104 cells per 
well and cultured in DMEM supplemented with 10% FBS (v/v) for 
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1700630 (10 of 11)
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24 h. Then the cells were rinsed by PBS and treated with different 
samples (BGNC@miRNA, BGN@miRNA, BGNC, and BGN). After 
being incubated for 24 h, the medium were changed to osteogenic 
inductive medium. The medium were replaced by fresh medium every 
3 d. At every specific time point, cells were collected and total RNA 
were extracted using Tripure (Roche), then single-stranded cDNA was 
synthesized using a RevertAid First Strand cDNA Synthesis kit (Roche) 
according to manufacturer’s instructions. qRT-PCR was carried out by 
employing iTaq universal SYBR Green supermix (Applied Biosystems 
7500, Bio-rad) with the gene-specific primers listed in Table S1 
(Supporting Information). The qRT-PCR amplifications were conducted 
under 95 °C for 5 min, 40 cycles of 95 °C for 10 s, 60 °C for 30 s, and 
70 °C for 10 min.
Critical-Sized Bone Regeneration Evaluation In Vivo: The in vivo bone 
regeneration ability of BGNCs and BGNC@miRNA were investigated 
by a rat cranial critical sized defect model (5 mm in diameter, Sprague 
Dawley rats, six weeks, male, 200–220 g). Animal surgeries and 
euthanasia work was conducted in compliance with the animal care and 
use guidelines of National Institutes of Health and the animal research 
committee of Xi’an Jiaotong University. Briefly, the rats were narcotized 
with 10 wt% chloral hydrate under a rigorous aseptic condition (n = 
6 per group), 5 mm diameter defects were made at the both sides of 
calvarium. Before implantation, samples were mixed with biomedical 
fibrin glue (Porcine Fibrin Sealant Kit, Hangzhou Puji Pharmaceutical 
Technology) at a weight ratio of 1:1. The as-prepared hybrid solution 
could be formed to hydrogel in defect site once implantation. The critical 
sized defect was filled with fibrin glue hydrogel containing BGN, BGN@
miRNA, BGNC, BGNC@miRNA, using pure fibrin glue hydrogel as a 
negative control (NC). After implantation for four weeks, the rats were 
sacrificed, and the implanted materials/surrounding native bones were 
dissected and fixed in 10% neutral buffered formalin for microCT analysis 
and histological evaluation. MicroCT analysis was performed on a 3D 
microfocus X-ray microcomputed tomography system (Y.CHEETAH*, 
YXLON) to quantitatively analyze the newly formed bone within the 
defects. For the histology evaluation, bone samples were decalcified in 
10% EDTA and embedded in paraffin. Then the samples were sectioned 
(5 µm thick) and stained with H&E, Sigma and Masson’s trichrome 
(Sigma), respectively. The bone volume and trabecular thickness was 
calculated based on the microCT analysis. At least three rats per group 
were evaluated.
Statistical Analysis: All results were expressed as mean value ± 
standard deviation. SPSS Statistics software (version 13.0) was utilized 
for all the statistical analysis, and Student’s t-test was carried out to 
evaluate the statistically significant differences between two groups. It 
was considered that the differences were significant when *p values < 
0.05 or **p < 0.01. All experiments were performed at least in triplicate.
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Supporting Information is available from the Wiley Online Library or 
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